On January 7, the management department of the Science and Technology Innovation Board of the Shanghai Stock Exchange issued a decision to supervise and warn Shenzhen Yahuilong Biotechnology Co., Ltd. and those responsible. Currently, “brain-computer interface” is a hot concept in the market, and investors pay great attention to it. In particular, the company's stock price closed up 6.52% on the same day, and the trading volume increased 299% from the previous trading day. The company should be particularly cautious in disclosing information relating to hot topics to ensure that the disclosure of relevant information is true, accurate, and complete, and avoid misleading investors. The company's relevant announcements were inconsistent about whether the partner's brain and computer Starlink technology path included intrusive statements, nor did they sufficiently alert investors to risks on key issues of concern, such as cooperative synergy, feasibility, and uncertainty about subsequent cooperation. The disclosure of information was inaccurate and incomplete. The management department of the Science and Technology Innovation Board of the Shanghai Stock Exchange made the following regulatory decisions: Wang Mingyang, who was the current secretary of the board of directors of Shenzhen Yahuilong Biotechnology Co., Ltd. was supervised and warned.

On January 7, the management department of the Science and Technology Innovation Board of the Shanghai Stock Exchange issued a decision to supervise and warn Shenzhen Yahuilong Biotechnology Co., Ltd. and those responsible. Currently, “brain-computer interface” is a hot concept in the market, and investors pay great attention to it. In particular, the company's stock price closed up 6.52% on the same day, and the trading volume increased 299% from the previous trading day. The company should be particularly cautious in disclosing information relating to hot topics to ensure that the disclosure of relevant information is true, accurate, and complete, and avoid misleading investors. The company's relevant announcements were inconsistent about whether the partner's brain and computer Starlink technology path included intrusive statements, nor did they sufficiently alert investors to risks on key issues of concern, such as cooperative synergy, feasibility, and uncertainty about subsequent cooperation. The disclosure of information was inaccurate and incomplete. The management department of the Science and Technology Innovation Board of the Shanghai Stock Exchange made the following regulatory decisions: Wang Mingyang, who was the current secretary of the board of directors of Shenzhen Yahuilong Biotechnology Co., Ltd. was supervised and warned.